The drug development process is fraught with complexities and bottlenecks that can slow progress. To make informed decisions, researchers need access to comprehensive, accurate scientific data, especially when uncovering unexpected benefits or adverse effects during exploratory development.

However, the adoption of costly, resource-intensive technologies can be a significant hurdle. This webinar will demonstrate how integrating high-plex proteomics services can help overcome these barriers, accelerating decision-making throughout drug development. Proteomic insights are increasingly shaping every stage of the drug discovery and development pipeline. By analyzing protein and single-cell interactions, we can gain a deeper understanding of disease mechanisms, immune potency and persistence, immune-related adverse events, and immunosuppression.

Join us to learn how leveraging proteomics services—ranging from spatial proteomics to flow cytometry to ultra-high-plex techniques—can de-risk your projects and provide the broadest immune coverage available, maximizing insights and driving faster, more confident evidence-based decisions.

Please Note: Due to audio issues we are re-recording a portion of this webinar prior to on-demand publication. In the meantime, you can continue to register, and will be notified when the updated recording is available. Thank you for your patience!

Key Topics Include:

  • Discover how proven proteomics platforms can help address the challenges of reproducibility, enabling you to obtain consistent, high-quality data over time and across multiple studies.
  • Explore how leveraging Standard BioTools Services allows you to access world-leading proteomics technologies without the need for expensive equipment or specialized in-house expertise enabling you to make breakthrough in research and accelerate your progress towards impactful solutions.
  • Discover how the integration of advanced tools, such as spatial proteomics and ultra-high-plex techniques, delivers actionable insights, enhances research precision, and reduces risk in your projects.
  • Gain practical knowledge on leveraging proteomics for faster, more confident decision-making, driving efficient and successful outcomes throughout the drug discovery pipeline.

Presenters

Stephen A. Williams, ;M.D., Ph.D

Stephen A. Williams, M.D., Ph.D

Chief Medical Officer
Standard BioTools

Stephen Williams, M.D., Ph.D. has been the Chief Medical Officer at SomaLogic since 2009, and is responsible for Clinical R&D, Medical Affairs and Regulatory and Quality. He oversees clinical application of the SomaScan® Platform and has also had roles in launching the life sciences commercial business, assay development and bioinformatics.
Nina Lane, ;Ph.D.

Nina Lane, Ph.D.

Product Manager
CyTOF/IMC Service Lab
Standard BioTools

Nina Lane, Ph.D., has been at Standard BioTools since 2016. She started her industry career as a Field applications specialist within EMEA. After 4 years and relocating to Canada, she worked as a Product applications specialist before becoming a Product Manager in 2021. She is responsible for CyTOF/IMC studies, managing a busy service lab, and executing bioinformatics services. Over the last 9 years, she has worked with Academics, pharmaceuticals, and Biotechs on a variety of studies, from Pre-clinical to Phase 2 studies.

Production Partner

Additional Content From Scientist.com

Related Content